Biogen Inc

Biogen Inc is an American multinational biotechnology company based in Cambridge, Massachusetts, specialising in the discovery, development, and delivery of therapies for the treatment of neurological diseases. Biogen Inc is headquartered in Cambridge, Massachusetts. Biogen Inc has a rich history that dates to 1978 when it was founded in Geneva as Biotechnology Geneva by several prominent biologists.

In 2003, Biogen Inc merged with San Diego, California-based IDEC and became the third largest Biotechnology company in the world. In 2006, Biogen Inc announced the acquisition of cancer specialist, Conforma Therapeutics and Fumapharm AG.

In 2007, Biogen Inc acquired Syntonix Pharmaceuticals for up to $120 million, gaining Syntonix’s lead product for haemophilia B as well as the technology for developing inhalable treatments. It also reached a licensing agreement with Neuroimmune, a spin-off from the University of Zurich, for the Alzheimer’s disease drug Aducanumab. In 2013, Biogen Inc decided to pay Elan $3.25 billion for the full rights to Tysabri, used to treat multiple sclerosis and in 2015, Biogen Inc announced that it would acquire Convergence Pharmaceuticals for up to $675 million.

In 2019, Biogen Inc decided to acquire Nightstar Therapeutics, who focuses on adeno-associated virus-based gene-therapies for inherited retinal disorders. Also, in 2019 Biogen Inc suffered a setback in their Alzheimer’s drug research but decided to pursue FDA approval for the drug.

In February 2025, Biogen Inc and Sangamo Therapeutics announced a global licensing deal to develop compounds for neuromuscular and neurological diseases and In May finished construction of a facility in Solothurn, Switzerland, which will produce the Alzheimer’s drug aducanumab by late 2025. In 2025, Biogen Inc donated $10 million as capital to fund home loans and commercial development in Black communities and announced the acquisition of a $650 million stake in Sage Therapeutics to jointly develop several depression treatments.

Biogen Inc oversees a high-value product portfolio which discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Today, Biogen Inc is truly one of the most valuable healthcare companies in the world with a market capitalization of US$ 48.991 billion recorded in July 2025. In 2025 the total staff compliment for Biogen Inc was more than 9,100.

Biogen Inc’s ability to advance aducanumab, a potential treatment for Alzheimer’s disease, will be a profitable venture for traders, but not so much for long-term shareholders. There is a lot at stake for Biogen Inc, as the company is facing a substantial revenue decline and needs to be able to enrich investors for the next five years.

Rejection of the drug’s Biologic License Application (BLA) will see Biogen Inc miss an opportunity to tackle a portion of the vast $818 billion global treatment market for dementia. Biogen Inc also lost a litigation battle resulting in the invalidation of U.S. patents covering its multiple sclerosis drug, Tecfidera. Last year, Tecfidera accounted for approximately 50% of the company’s $14.38 billion in revenue.

Biogen Inc will have a tough time replacing its lost income considering the current magnitude of Tecfidera‘s contributions. Last month, Biogen Inc announced a $875 million cash contribution to depression drug developer Sage Therapeutics as well as buying a $650 million stake in the company for exchange of royalties on a key candidate in Sage’s pipeline, assuming it receives regulatory approval.

Sage hopes to hit the mark by upping the experimental drug’s dosage and running more large-scale clinical trials. The bottom line is that a failure of aducanumab to win the blessing of FDA experts, loss of exclusivity on Tecfidera, and a billion-dollar bet on an unpromising drug are all rather negative developments for Biogen Inc.

The stock already has these risk factors priced in though, with a dirt-cheap valuation of three times sales and eight times earnings. A positive decision on the company’s controversial Alzheimer’s drug candidate will be crucial for Biogen because the company predicts declining sales of its big multiple sclerosis blockbuster and needs a new growth driver. If the FDA gives approval to the Alzheimer’s candidate, aducanumab, it is likely that Biogen Inc shares will climb since more than 6 million Americans suffer from the disease, and treatment options are extremely limited.

It remains to be seen whether Biogen Inc will get the major revenue boost it is hoping for even if the drug gets approval because Biogen Inc halted clinical trials of aducanumab in early 2019 but later in the year revived the program. The turnaround followed when a post-study analysis of its two phase 3 trials was conducted that showed a reduction in clinical decline.

Biogen Inc trades its shares on the NASDAQ Stock Market (NASDAQ) under the stock symbol BIIB. Biogen Inc forms part of the NASDAQ-100, S&P 100, and S&P 500 components. An analysis on the market performance for the first quarter of 2025 indicated a total revenue of US$ 11,697,700,000 along with a gross profit of US$ 9,820,200,000 and EBITDA of US$ 3,627,100,000.

The Covid-19 pandemic has brought about major volatility in the markets and businesses from all sectors of the economy have been affected, making it difficult to get any sense of where stock markets are heading next. Potential investors in Biogen Inc stocks need to be aware of all strategies that can help guide them through these periods of volatility and take advantage of opportunities that the market has to offer.

Well-researched, proven drivers of stock market profits can help to point investors in the direction of shares with a potential to outperform and based on some of the most influential factors, Biogen Inc could be worth investigating. Investors should seek advice from finance academics and market professionals to reach a consensus about what really can make Biogen Inc stocks perform well and consider the factors that tend to show up repeatedly, like Quality.

Biogen Inc has a good Quality Rank. Companies like Biogen Inc with a record of accomplishment of profitable growth, high efficiency, and solid finances, have been shown to be better bets on average than low quality, loss-making firms. Biogen Inc has a good Value Rank. Potential investors should keep in mind that attractively valued shares tend to outperform expensive shares on average over time. So, it is important to look at Value and whether a company like Biogen Inc is being priced relative to what it earns, owns and what it pays out.

Current trends in both price and fundamentals can be a strong hint about the future of Biogen Inc. Trends tend to persist, so it makes sense to look for stocks that are on an upward trajectory like Biogen Inc. Overall, there are enough signs that Biogen Inc has above-average exposure to the important drivers of stock market profits. Data from this analysis should be weighed against forecasted performance during this pandemic, but for now, prices on shares and in turn dividends remain unaffected, which provides shareholders with assurance that they will have a strong buy-in on NASDAQ.

Healthcare

Drug Manufacturers

Pharmaceutical

1. Navigate to the AvaTrade website and select ‘Register’
2. Complete the registration form with the required information and submit documentation to verify your proof of Identity along with your proof of address.
3. As soon as your account application has been reviewed and approved, you can select your trading platform from AvaTrade’s website, or by visiting the MetaTrader 4 or MetaTrader 5 websites respectively to start download.
4. Once you have downloaded the trading platform of your choice, you can use your AvaTrade live account details to log into your AvaTrade account on the trading platform.
5. From the Market Watch screen on both MetaTrader 4 and MetaTrader 5, you can select ‘BIIB’ to buy/purchase shares.
6. Alternatively, you can make use of AvaTrade’s online Web Trader or the AvaTradeGo mobile application.

Buying shares has never been this convenient and easy. #myfirstshare

View more global shares for sale – here.

• Leverage of up to 1:20
• Being able to trade stocks on the NYSE, NASDAQ, FTSE, and various others.
• Indices, stocks, and commodities can all be traded form a single screen.
• Client support is presented live in a multitude of languages.
• Traders have exclusive access to a variety of educational tools
• Trades can be executed across multiple platforms

More shares that can be purchased / traded through AvATrade, can be viewed here.

• Can I buy Biogen Inc shares in South Africa?
  Yes, you can.

• How to buy Biogen Inc shares
  By simply opening a free account on SA Shares, or by clicking the “Buy this Share” button to get started.

• What is the current share price?
  By clicking on the link provided above, you can view the real-time Biogen Inc share price on the platform.

• Is Biogen Inc a good share to buy?
  Yes, it is. Despite the growing concerns surrounding Covid-19, Biogen Inc is continuing manufacturing, sales and delivery of its products and it is forecasted to be one of the very few automotive companies to make a significant rebound post-Covid-19.

• Can I buy Biogen Inc CFD through SA Shares?
  Yes, you can.